信立泰：关于SAL0140药品临床试验申请获得受理的公告

Core Viewpoint - The company, Xinlitai, has received approval from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0140 tablets [1] Group 1 - Xinlitai announced the receipt of the acceptance notice for its clinical trial application [1] - The drug SAL0140 is identified by the project code SAL0140 [1]